VIRUSES #038; VACCINES PUBLIC HEALTH MENTAL HEALTH DISEASES TECHNOLOGY POLICY #038; LAW ENVIRONMENT RESEARCH VIRUSES #038; VACCINES PUBLIC HEALTH MENTAL HEALTH DISEASES TECHNOLOGY POLICY #038; LAW ENVIRONMENT RESEARCH .columns" VIRUSES amp; VACCINES Risk of HIV Related Heart Disease Risk Varies by Geography, Income April 2, 2020 by News 0 People living with human immunodeficiency virus (HIV) infection are at higher risk of cardiovascular disease (CVD) compared to people without HIV. Data linking HIV and CVD, CVD risk factors and CVD risk assessment come predominantly from North America and Europe. However, of the estimated 37.9 million people living with HIV worldwide, two thirds (25.6 million) live in sub Saharan Africa, where less is known about rates of incident CVD and the burden of risk factors driving CVD risk.
Bacteria like Streptococcus pneumoniae complicate viral infections like the flu, H1N1, and Covid 19. CDC The ongoing Covid 19 pandemic highlights the critical need for rapid development of vaccines and antiviral treatments to reduce the number of hospitalizations and deaths caused by this dangerous new coronavirus, SARS CoV 2. The biopharmaceutical industry has quickly responded and at least 80 candidates are already in development. With good luck, we will eventually have some of the tools we need to fight this new global threat.
The experience of developing vaccines for diseases like Ebola has led some companies to be more cautious with their investments.
In Depth Study of the Neglected Tropical Diseases Drugs and Vaccines MarketNeglected Tropical Diseases Drugs and Vaccines , in its newly released Market research report, provides an understanding of the many different facets of the Neglected Tropical Diseases Drugs and Vaccines market. The all round analysis of this Neglected Tropical Diseases Drugs and Vaccines market depicts the data and throws light. The demand side and supply side styles are monitored to offer a very clear picture of this industry scenario across different geographies.
;The Most Recent study on the Neglected Tropical Diseases Drugs and Vaccines Market Research provides a profound comprehension of the various market dynamics like trends, drivers, the challenges, and opportunities. The report further elaborates on the micro and macro economic elements that are predicted to shape the increase of the Neglected Tropical Diseases Drugs and Vaccines market throughout the forecast period (2019 2029).
Transparency Market Research, in its latest market intelligence study, finds that the global Neglected Tropical Diseases Drugs and Vaccines market registered a value of US$ xx Mn Bn in 2018 and is expected to expand at xx% CAGR during the forecast period 2019 2029. All the trends and patterns of consumption and adoption of the Neglected Tropical Diseases Drugs and Vaccines are covered in the report.Prominent players, including player 1, player 2, player 3 and player 4, among others, account for substantial shares in the global Neglected Tropical Diseases Drugs and Vaccines market. The Neglected Tropical Diseases Drugs and Vaccines market study outlines the key regions - Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2), region 3 (Country 1, Country 2) and region 4 (Country 1, Country 2).
The Board of Gavi announced during a meeting in New Delhi, India, that an expanded stockpile of Ebola vaccines will become available in 2020.This announcement on December 5, 2019, said an estimated investment of $178 million dollars will be needed through 2025 to fund this new Ebola vaccine program.
Musuniene, a large village about an hour''s drive outside the city of Butembo, sits within territory held by the Mai Mai armed group. Despite the security risk, a vaccination team is in place to make sure that a number of people who are listed as contacts of Ebola patients and who have recently travelled to Musuniene are reached with vaccines. They are also vaccinating first line health workers who have recently joined the team to serve in Ebola transit centres. When Kambale heard radio messages about the ring vaccination campaign, he decided the best course of action would be to bring the children to the health centre. Under the protocols implemented by WHO, all those who are contacts of people who have been diagnosed with Ebola, everyone who is a contact of a contact, and all those who are probable contacts anyone in a health zone where there is a confirmed case are eligible to receive the vaccine. I am also very happy because those who vaccinated me are the people who speak my language, so I could talk with them and ask them a few questions without difficulty, adds Kambale. The fact that the vaccinations are carried out by local people has been critical to the success of the campaign. As part of the activities on preparedness for the threat of Ebola, four teams of vaccinators 60 people in all arrived in North Kivu province in August 2018 to assist with the vaccinations. The team included Guineans, one person from Niger, and Congolese, all of whom were perceived as outsiders even the Congolese, who had been trained in the capital, Kinshasa. But as Sister Zawadi Fikiri, manager of the Musuniene General Hospital, explains, Initially, there was a lot of resistance among the local people because the vaccinators were foreigners.
Onchocerciasis is caused by the infection of a specific type of parasitic worm inside the human body. The parasite is almost always transferred to the human body by black flies through biting. Global statistics show that onchocerciasis is the second highest infection based cause of blindness in the world, second only to trachoma. Common symptoms of onchocerciasis include bumps under the skin, excessive itching, and finally blindness. Studies show that a patient needs to be bitten for a large number of times to contract onchocerciasis.There are, unfortunately, no vaccines present that can eradicate onchocerciasis. The most common form of cure for onchocerciasis is prevention, which is largely done using insect repellents or fully protective clothing near or inside rivers. Additional research and development is also being made towards the use of specialized insecticides that can help eliminate black flies, while from a medical perspective, the people living close to rivers can be given protective treatments twice a year. Common treatment includes the administration of a drug named ivermectin once every six to twelve months. However, it should be noted that ivermectin only destroys the larva without killing the adults. They can be weakened using doxycycline, an antibiotic that kills the bacteria associated with the adults. Additionally, surgical treatment may be recommended to patients in order to remove the lumps under their skins. The WHO lists onchocerciasis as a neglected tropical disease, and approximately 15.5 mn people are known to be suffering from it.
IN 2016 THE World Health Organisation (WHO) declared Britain to be officially free from measles, a highly infectious illness that killed about 110,000 people around the world in 2017. The success was short lived. After 991 infections were recorded in England and Wales in 2018, the WHO revoked Britain s disease free label.Cases of measles are rising in many countries, fuelled in part by conspiracy theories claiming that vaccines given to children cause autism (they do not). Anti vaxxers have long used internet forums and social media to spread their nonsense. Matt Hancock, Britain s health minister, would like to see that stopped. In March he said that internet giants such as Facebook and Google should have a duty of care to their users, putting them in the same legal position as schools or doctors. If firms would not stop the spread of anti vaccination messages voluntarily, said Mr Hancock, he would consider changing the law to force them to do so.
While searching for a new approach in vaccine development for dengue, researchers discovered that the dengue virus changes its shape through mutations in envelope protein to evade vaccines and therapeutics.DENV2 (a dengue virus) exists as smooth spherical surface particles while growing at the mosquito 's physiological temperature (29 degrees Celsius). It then changes to bumpy surfaced particles at human physiological temperature (37 degrees Celsius).
The study focused on a class of viruses known as enteroviruses, a category which includes rhinoviruses, the culprits behind common colds. Most of us catch rhinoviruses through encountering virus particles spread by an infected person, through the air, on surfaces, or body contact, according to the Mayo Clinic which is why it's so important to cover your mouth when you sneeze and sanitize your hands when you have a cold. Once rhinoviruses enter the human body, they replicate; they actually don't like our body temperature, so they tend to replicate best in colder areas like your nasal passages. There's no treatment beyond simply waiting for the cold virus to pass, because antibiotics are no use against it and no effective vaccines exist.The new study looked at the structure of enteroviruses themselves to see if they could be prevented from replicating. The researchers found that enteroviruses, including rhinoviruses, actually need something in infected human and mammal cells in order to replicate successfully. They can't do it themselves. Using two different kinds of enteroviruses, the scientists found that when cells were lacking a certain gene, enteroviruses could infect them but couldn't replicate, stopping the virus in its tracks.
Ebola has emerged as a major hazard to mankind in recent years. Though the Ebola virus and the disease caused by it have been familiar to science for decades, the risk of a global epidemic has increased massively due to the advances in globalization. The recent outbreak of Ebola in West Africa has brought the disease in the global spotlight.Ebola starts out as a sore throat, muscle pain, headache, and fever. It is a viral hemorrhagic fever, which means the patient bleeds internally as well as externally. The function of the liver and the kidneys is also hampered significantly by the Ebola virus. The lack of a reliable cure for Ebola is the primary driver for the global Ebola drug and vaccines market, with the need to come up with a solution being among the most urgent and financially among the most lucrative in the world.
The warning came as the death toll for the Ebola outbreak in the DRC has been approaching 2,000 and as the total number of cases reaches 3,000.The effective new treatments and continued roll out of vaccines alone, according to IFRC's Director of Health and Care Emanuele Capobianco, have been not enough.
Burundi has begun to vaccinate its frontline health workers against Ebola using unlicensed vaccines.
Aug 6, 2019 Reuters 0 By Kate Kelland
More than 130,000 people have been vaccinated by health workers during the nearly year long epidemic in eastern Democratic Republic of Congo with an experimental vaccine manufactured by Merck that has proven highly effective.But the outbreak, which is the second worst in history, continues to spread, due largely to mistrust by people in eastern Congo of the response and armed attacks against health workers that have limited access to patients.